<?xml version="1.0" encoding="UTF-8"?>
<p id="Par104">The VelocImmune mouse is a second generation transgenic chimeric mouse and has yielded four approved drugs (Table 
 <xref rid="Tab5" ref-type="table">5</xref>). Dupilumab (Dupixent, Sanofi and Regeneron, human IgG4) binds to IL-4 receptor and inhibits the IL-4 and IL-13 pathway, as an eczema treatment. Sarilumab (Kevzara, Sanofi and Regeneron, human IgG1) inhibits IL-6 signaling by binding to the IL-6 receptor (IL-6R), which otherwise would upregulate the release of rheumatoid arthritis-related factors from hepatocytes. The two drugs were both approved in 2017. Notably, despite having access to the XenoMouse and owning Cambridge Antibody Technology (the phage display company behind Humira), AstraZeneca paid over $120 million for a few breeding pairs of VelocImmune mice [
 <xref ref-type="bibr" rid="CR193">193</xref>].
</p>
